Annals of Surgical Oncology

, Volume 18, Supplement 3, pp 286–287 | Cite as

Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment

Breast Oncology


Breast Cancer Trastuzumab Oncological Outcome Inflammatory Breast Cancer Breast Cancer Experience 


  1. 1.
    Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, et al. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011;18:932–8.PubMedCrossRefGoogle Scholar
  2. 2.
    de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467:543–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 2011;11:81–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med. 2010;4(4):583–6. No abstract available.PubMedCrossRefGoogle Scholar
  6. 6.
    Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn. 2010;10(5):541–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics. 2010;11(8):1039–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Roukos DH. Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices. 2011;8(4):409–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH. Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics. 2011;12(5):695–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices. 2011;8(2):123–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Roukos DH. Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol. 2011;18(1):12–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices. 2010;7(6):723–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Personal Med. 2010;7(4):347–50.CrossRefGoogle Scholar
  14. 14.
    Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther. 2010;10(2):123–8.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  1. 1.Department of SurgeryUniversity Hospital of Ioannina, School of MedicineIoanninaGreece

Personalised recommendations